iRhythm Technologies (IRTC) The Baird 2024 Global Healthcare Conference summary

Strategic vision and growth outlook

• Leadership is highly optimistic about future growth, focusing on innovation and profitability over the next five years.

• The company is expanding its platform capabilities through a licensing deal with BioIntelliSense, aiming to add new sensing parameters and broaden clinical insights.

• Long-term plans include moving from a cardiac diagnostic device company to a broader monitoring platform, targeting heart failure, hypertension, and sleep disorders.

• International expansion is underway, with launches in Austria, Switzerland, Netherlands, Spain, and anticipated entry into Japan in early 2025.

• Growth levers include international markets, new product launches, and increased primary care and asymptomatic screening adoption.

Competitive positioning and innovation

• Maintains a strong market share (~70%) in long-term continuous cardiac monitoring, despite increased competition.

• Recent product innovation includes the Zio Monitor, which replaced Zio XT and improved wear times and user experience.

• Clinical data, especially from the Camelot study, has been pivotal in establishing product superiority and supporting commercial efforts.

• Ongoing investment in AI, hardware, and form factor innovation to sustain competitive advantage.

Regulatory and quality management updates

• Addressing FDA Form 483 observations and a warning letter, with remediation as the top corporate priority.

• Submitted responses to the FDA and brought in a new head of quality to oversee improvements.

• Two 510(k) submissions are progressing, with expected clearances in September–October; Zio MCT submission targeted by year-end and launch in the second half of 2025.

• Quality management system updates may be required to include certified cardiac technicians, per FDA feedback.